SPUR

SPUR™ is an AI-enabled behavioral diagnostic and digital engagement solution developed by Clinical ink, designed to optimize patient retention and adherence in clinical trials. It addresses one of the most critical challenges in drug development: every participant who discontinues a study drug, fails to follow the protocol, or drops out reduces the statistical power and credibility of the study. SPUR™ provides a validated, individualized behavioral diagnosis and a personalized intervention plan for each trial participant.

SPUR™ is proven to improve patient medication adherence and clinical outcomes across multiple therapeutic areas, making it a powerful tool for research investigators, clinical operations teams, and sponsors seeking to protect study integrity and data quality.

Key Features and Capabilities

• Participant Engagement: A simple, validated electronic questionnaire is administered to each participant, feeding directly into the SPUR™ analysis engine and providing immediate supportive feedback to the individual.
• Instant Analysis: Research investigators receive a detailed participant profile that predicts the risk of poor adherence, identifies the specific drivers of that risk, and delivers personalized communication guidance to improve engagement and adherence.
• Behavioral Evaluation: SPUR™ evaluates four key determinants of patient beliefs, attitudes, and behaviors — Social, Psychological, Usage, and Rational (SPUR) — producing a unique behavioral profile for every patient or research participant.
• AI-Driven Personalized Support: Powered by a proprietary AI engine, SPUR™ dynamically adjusts how it engages each participant by adapting the frequency, tone, and content of messages, ensuring that every interaction is personalized and motivating.

Scientific Foundation

• SPUR™ is built on evidence-based frameworks for understanding and improving adherence to prescribed treatment and protocol engagement.
• The platform applies validated behavioral science to identify adherence risk at the individual level, enabling targeted and timely interventions.
• Clinical ink offers educational resources, including an on-demand webinar in which expert speakers discuss the importance of adherence in both clinical practice and the drug development setting, examining key frameworks for risk identification and personalized digital interventions.

Workflow Overview

1. Each trial participant completes a simple, validated electronic questionnaire within the SPUR™ platform.
2. The proprietary AI engine analyzes responses to generate an individual behavioral profile across the four SPUR determinants.
3. Research investigators receive an instant risk prediction, a driver analysis, and personalized communication guidance.
4. The system dynamically adjusts ongoing participant engagement — including message frequency, tone, and content — based on each individual's profile and evolving needs.

SPUR™ is part of the broader Clinical ink digital clinical trial platform, which also encompasses eSource, eCOA, eConsent, and other solutions. A white paper is available for download detailing how SPUR™ improves patient medication adherence and clinical outcomes across therapeutic areas.